As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Rapport Therapeutics, Inc. The largest reported stake is Third Rock Ventures V, L.P.'s, at 13.1%. 9 filings are on record since September 18, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Rapport Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Third Rock Ventures V, L.P. · Sole voting: 0 · Shared voting: 6,280,525 · Sole dispositive: 0 · Shared dispositive: 6,280,525 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 2,657,521 · Sole dispositive: 0 · Shared dispositive: 2,657,521 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Capital International Investors · Sole voting: 2,921,958 · Shared voting: 0 · Sole dispositive: 2,921,958 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-12
- · Holder: Cormorant Asset Management, LP · Percent: 6.19% · SCHEDULE 13G/A
- · Holder: Cormorant Asset Management, LP · Percent: 6.35% · SCHEDULE 13G/A
Rapport Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-09-18. 4 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 13.1% | 6,280,525 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Capital International Investors | 6.1% | 2,921,958 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Cormorant Asset Management, LP | 5.56% | 2,657,521 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 5.03% | 2,397,549 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| Johnson & Johnson | 4.9% | 1,784,517 | SCHEDULE 13G/A, 2025-10-22 | 2025-09-30 |
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.2% | 1,863,327 | SCHEDULE 13D/A, 2025-09-18 | 2025-09-11 |
Holding shares or following this stake? See who's behind Rapport Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Rapport Therapeutics, Inc. and the records around it.
Rapport Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- JOHNSON & JOHNSON also filed stake reports on 2 other companies: Rallybio Corporation (Apr 2026), CVRx, Inc. (Jan 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Watch Rapport Therapeutics, Inc.
Get an email when Rapport Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rapport Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rapport Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rapport Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 0 | 6,280,525 | 0 | 6,280,525 | SCHEDULE 13G/A, 2026-08-14 |
| Third Rock Ventures GP V, L.P. | 0 | 6,280,525 | 0 | 6,280,525 | SCHEDULE 13G/A, 2026-08-14 |
| Trv Gp V, LLC | 0 | 6,280,525 | 0 | 6,280,525 | SCHEDULE 13G/A, 2026-08-14 |
| Third Rock Ventures VI, L.P. | 0 | 969,218 | 0 | 969,218 | SCHEDULE 13G/A, 2026-08-14 |
| Third Rock Ventures GP VI, L.P. | 0 | 969,218 | 0 | 969,218 | SCHEDULE 13G/A, 2026-08-14 |
| Trv Gp Vi, LLC | 0 | 969,218 | 0 | 969,218 | SCHEDULE 13G/A, 2026-08-14 |
| Capital International Investors | 2,921,958 | 0 | 2,921,958 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| Cormorant Asset Management, LP | 0 | 2,657,521 | 0 | 2,657,521 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 2,657,521 | 0 | 2,657,521 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Rapport Therapeutics, Inc. by CUSIP 75383L102 and gives its principal executive office as 1325 Boylston Street, Suite 401, Boston, MA 02215 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
The V shares represent approximately 13.1% of the outstanding shares of Common Stock. The VI shares represent approximately 2.0% of the outstanding shares of Common Stock. The percent of class was calculated based on 47,978,286 shares of common stock issued and outstanding as of August 3, 2026, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on August 5, 2026.Third Rock Ventures V, L.P., SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Sofinnova Venture Partners XI, L.P. ("SVP XI")
The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2025-09-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-18 | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.2% | SCHEDULE 13D/A |
| 2025-10-22 | Johnson & Johnson | 4.9% | SCHEDULE 13G/A |
| 2025-11-14 | Cormorant Asset Management, LP | 6.7% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.03% | SCHEDULE 13G |
| 2026-02-17 | Cormorant Asset Management, LP | 6.35% | SCHEDULE 13G/A |
| 2026-05-15 | Cormorant Asset Management, LP | 6.19% | SCHEDULE 13G/A |
| 2026-08-12 | Capital International Investors | 6.1% | SCHEDULE 13G/A |
| 2026-08-14 | Cormorant Asset Management, LP | 5.56% | SCHEDULE 13G/A |
| 2026-08-14 | Third Rock Ventures V, L.P. | 13.1% | SCHEDULE 13G/A |
Questions about who owns Rapport Therapeutics, Inc.
Who owns Rapport Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Rapport Therapeutics, Inc.: Third Rock Ventures V, L.P. (13.1%, Schedule 13G/A, filed 2026-08-14), Capital International Investors (6.1%, Schedule 13G/A, filed 2026-08-12), Cormorant Asset Management, LP (5.56%, Schedule 13G/A, filed 2026-08-14) and BlackRock, Inc. (5.03%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Rapport Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Rapport Therapeutics, Inc. on this page are Third Rock Ventures V, L.P. (13.1%), Capital International Investors (6.1%) and Cormorant Asset Management, LP (5.56%).
When did Third Rock Ventures V, L.P. buy into Rapport Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Third Rock Ventures V, L.P. on this page is the Schedule 13G/A, filed 2026-08-14, reporting 13.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Rapport Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.